Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
P/B ratio for Onconova Therapeutics, Inc. (ONTX)
P/B ratio as of 2023: 38.84
According to Onconova Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 38.84. At the end of 2022 the company had a P/B ratio of 12.00.
P/B ratio history for Onconova Therapeutics, Inc. from 2011 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 38.84 |
| 2022 | 12.00 |
| 2021 | 23.27 |
| 2020 | 331.16 |
| 2019 | 11.81 |
| 2018 | 40.38 |
| 2017 | -28.87 |
| 2016 | 58.46 |
| 2015 | 2.44 |
| 2014 | 3.13 |
| 2013 | 3.06 |
| 2012 | -2.59 |
| 2011 | -2.96 |